Objectives: CDK2 is a protein that plays a role in regulating the cell cycle where its overexpression contributes to uncontrolled cell proliferation. Inhibition of CDK2 has been known to be one of the mechanisms of various anticancer drugs. Curcumin is an active compound of Curcuma Longa which have been reported to inhibit the activity of Cyclin D, Cyclin E, CDK2, CDK4, and CDK6.
INTRODUCTION
Cancer is a condition of uncontrolled cell growth that can affect the growth of cells and / or other tissues around it through the circulatory system and lymphatic system. Therefore, research for new therapeutic agent on cancer treatment has always been a critical issue. The aim is to immediately address excessive cell proliferation and immediately prevent the metastatic process. At present, the molecular modelling approach, driven by the rapid development of computational chemistry, plays an important role in drug design and the discovery of new mechanisms from structure-based medicine. This method has successfully made many studies discover new drug 2 .
Some natural compounds are known to have the potential to become lead compounds in terms of inhibiting the growth of cancer cells, one of which is curcumin.
Curcumin is a hydrophobic polyphenols obtained from turmeric rhizome (Curcuma longa L.) and has been considered as an active anticancer substance 3, 4, 5 . Both preclinical and clinical studies have been carried to learn the anticancer effects of curcumin compounds, including its role in proliferation arrest of MCF7 breast cancer cells which is associated with their ability to inhibit cyclin D, cyclin E, CDK2, CDK4, and CDK6 activities and its ability to induce apoptosis through caspase-9 mechanism 6 . Therefore, the study of curcumin activity and the search for their active derivatives as new anticancer agents targetting CDK2 protein through the molecular modelling approach method is believed to be one of the best way to provide new alternative cancer treatment from the one that is currently available.
EXPERIMENTAL

Material
The hardware used in this study is a personal computer with the following specification:
Intel® Core™ i5-6600 CPU @ 3.90 GHz (4CPUs), Nvidia Geforce GTX 970 GPU 4
Gigabyte OC Edition, and 8 Gigabyte DDR4 RAM. The in silico testing uses softwares, that includes: The three-dimensional structure of the CDK-2 protein was downloaded from the Protein Data Bank (GDP) (http://www.rscb.org/) (ID: 1KE6) as well as the three-dimensional structure of curcumin and its derivates structure which is illustrated using ChemOffice 2010 software.
Receptor and Ligand Preparation
The CDK2 structure used in this study was downloaded from the Protein Data Bank 
RESULTS AND DISCUSSION
CDK2 Receptor Preparations
Cyclin dependent kinase-2 receptor (CDK2), downloaded from the Protein Data Bank 
Ligand Preparations
Ligand which are determined as the standard was obtained through a separation process with CDK2 receptors using the help of a software. Furthermore the test ligands, namely curcumin and its derivatives (kurkumod), were designed and optimized with the software described above. The consideration of the curcumin derivative design is based on keeping the original pharmacophore that has been found in the curcumin compound. 
Pharmacophore Modelling Result
The results of the phamacophore modelling will show the level of similarity between the modification of curcumin (kurkumod) to the standard CDK2 ligand (protein 1KE6 ligand).
Values of the pharmacophore similarity between these two compounds will be shown as 
u n c o r r e c t e d p r o o f
The molecular docking method aims to see the interaction between ligands, i.e curcumin and its derivatives with the target receptor, CDK2. The results of this process were the Gibbs free energy ∆G, inhibiton constant, number of clusters, and types of bonds to amino acid residues. The results of the curcumin docking and its derivate along with the standard CDK2 ligand against the CDK2 receptor itself can be seen in the Table 3 . Based on the results, modification of kurkumod 23 and 24 show that the value of ∆G tends to be lower than the modification of kurkumod 11, 17, and 20 although it has not been able to compensate for the free energy values of standard CDK2 ligands (ΔG -10.53) and modification 18, 21 and 19. Lower bond energy indicates that the interaction that occurs has a higher affinity because it tends to be easier (less energy) to interact. The cluster number of derivatives kurkumod 23 and 24 is also at the level where the first ranking cluster has more members than other clusters. More cluster numbers indicate that the poses of the conformation produced are more stable.
Table 3. Ligand Interaction with CDK2 active site
Consideration that kurkumod 23 and 24 are the best modifications of curcumin is based on the interactions that occur between these two derivatives with amino acid residues from the CDK2 receptor. Activation of CDK2 through complexation with cyclin A will induce conformational changes on the ATP binding site. The most significant effect is the rotation of helix C which causes changes in the geometry of the active side in the area of three active side catalyst residues, namely Lys33, Glu51, and Asp145. The Lys33 amino acid residue is considered as a potential interaction side for inhibitor compounds.
Carboxylic acid molecule which has been reported as an active CDK2 inhibitor is known to form hydrogen bonds with Lys-33 on CDK2 receptor residues. Therefore the kurkumod 23 and 24 which both form hydrogen interactions with Lys33 are considered as potential CDK2 inhibitors 10 . 
STUDY LIMITATION
This study are preliminary studies related to the design of derivatives of natural compounds that have potential as anticancer. The synthesis realization of the proposed compound, then in silico in vitro correlation anaylsis is expected in the future.
CONCLUSION
Based on the study result, it can be considered that kurkumod 23 and 24 are the best and most potential modifications of curcumin as CDK-2 antagonist, which is based on the interactions that occur between these two derivatives with amino acid residues from the CDK2 receptor 
